News

The CONQUER study was designed and conducted based on findings from subgroup analyses of prior Phase 3 studies of Emgality, which suggested it may be an option for

The study has achieved its co-primary endpoint of investigator-assessed progression-free survival (PFS). Roche’s combination of Tecentriq plus platinum-based chemotherapy demonstrated a statistically significant reduction in the risk of

The approval for Turalio is for the treatment of adults with rare joint tumour associated with severe morbidity or functional limitations and is not responsive to improvement through

Mahendra Deonarain, Antikor’s CEO and visiting Reader in Antibody Technology at Imperial College London where Antikor has its roots, commented: “We believe we have a platform that is

Sillajen has informed Transgene of the IDMC’s recommendation to stop enrolment in the study, as the study is unlikely to meet its primary objective by the time of

The phase 3 rivipansel evaluating safety, efficacy and time to discharge (RESET) study evaluated 345 patients who were randomised 1:1 to receive rivipansel or placebo, administered intravenously every

The agreement is an amendment to the terms of the 2006 tivozanib license agreement between Kyowa Kirin and AVEO which granted AVEO exclusive rights of tivozanib in all

The product is the generic version of Pierre Fabre Médicament’s Navelbine®, which is indicated for the treatment of advanced non-small-cell lung cancer (NSCLC) and advanced breast cancer. The

Nucala, a pre-filled pen and a pre-filled safety syringe, is claimed to be the only monthly anti-IL5 biologic approved in Europe to treat patients with severe eosinophilic asthma